Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypothyroidism

• Liothyronine

About Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs

Levothyroxine, available in a wide range of strengths from 25 mcg to 200 mcg, is a cornerstone medication for millions managing thyroid conditions. At TheDrugClub, we believe essential health shouldn't be a financial burden. Our members can often receive their levothyroxine prescription for a $0 co-pay, delivered free to their door, simplifying health management and making it more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs is approved for (FDA label)

Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including levothyroxine sodium, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (6 , 10) .

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

All tablets having functional scoring Levothyroxine sodium tablets USP are available as follows (Table 4): Table 4: Levothyroxine Sodium Tablet Strengths and Identifying Features Tablet Strength Tablet Description 25 mcg Round shaped, Orange colored, uncoated tablets, break line on both side and debossed with "P" and "1" on one side and plain on other side. Tablets (Functional Scoring): 25 mcg (3)

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

Adverse reactions associated with levothyroxine sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5) and Overdosage (10) ]. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy.

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4) ]. Uncorrected adrenal insufficiency. (4)

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

Serious risks related to overtreatment or undertreatment with levothyroxine sodium tablets: Titrate the dose of levothyroxine sodium carefully and monitor response to titration. (5.1) Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate levothyroxine sodium at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3 , 5.2 , 8.5) Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.3) Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium treatment. (5.4) Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements.

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Levothyroxine 25/50/75/88/100/112/125/137/150/175/200 mcg tabs (FDA label)

See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium. (7) 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium (Tables 5 to 8). Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents.

Source: FDA prescribing information (DailyMed). Set ID: 4c903249-69e9-4168-a9d1-22e6c2c1eb22. SPL document ID: 5b21fe77-f5e0-98fa-e063-6394a90afc8a. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.